Zacks Investment ResearchMon, 06 Apr 2026 18:10:38 GMTIMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study EndpointsIMVT+6.32%
Seeking AlphaThu, 02 Apr 2026 20:32:03 GMTImmunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update TranscriptIMVT+6.32%
The Motley FoolWed, 11 Mar 2026 16:48:23 GMTImmunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems BullishIMVT+6.32%
Zacks Investment ResearchThu, 05 Mar 2026 18:41:08 GMTImmunovant Stock Surges 17% in 3 Months: What's Driving It?IMVT+6.32%
